Educational Resources

A Toolkit For Those Living With or Care For Someone with Diffuse Large B-Cell Lymphoma (DLBCL)

Published: August 8, 2024

The purpose of this Toolkit is to help support your experience as someone living with Diffuse Large B-Cell Lymphoma (DLBCL) or as a care partner by providing information to help you build a deeper understanding of DLBCL. This Toolkit was created by a group of patients, care partners, advocates and healthcare professionals brought together by Incyte, a pharmaceutical company working on behalf of the DLBCL community.
View Resource

Implementing a Quality Intervention for Patients with Clinical Characteristics of Advanced Polycythemia Vera

Published on: July 30, 2024

This resource is a guide for pharmacy directors and clinical pharmacists to help clinicians identify the subset of patients with clinical characteristics of advanced polycythemia vera (PV).
View Resource

Identifying Patients with Advanced Polycythemia Vera

Published on: July 30, 2024

This resource is a step-by-step EMR guide for appropriate US population health decision makers or similar entities and their health systems to identify the subset of patients who may have clinical characteristics of advanced polycythemia vera (PV).
View Resource

What to Expect from Your Eye Care Appointments While Taking ELAHERE (mirvetuximab soravtansine-gynx)

Published on: July 18, 2024

This resource is intended for patients looking to:

• Understand what Ocular AEs may occur while on ELAHERE
• See what to expect during eye exams
• Review the important steps involved in proactively managing eye care while on treatment
• Learn the importance of communicating any side effects to your care team

Watch video

Best Practices for the Management of Ocular Adverse Events Associated with ELAHERE (mirvetuximab soravtansine-gynx)

Published on: July 18, 2024

This resource is intended for eye doctors or oncologists looking to:

• Understand why patients on ELAHERE require eye exams, and when
• Learn about what ocular AEs may be experienced by patients on ELAHERE
• Review the proactive eye drops administration patients should take during treatment
• See resources available to help facilitate communication between eye doctors and oncologists

Watch video

Help Patients Face the Realities of Life with Metastatic Breast Cancer Through Expose MBC

Published on: July 15, 2024

Gilead Oncology understands that metastatic breast cancer (MBC) is different from early breast cancer in many ways. Expose MBC is a platform for patients and their caregivers, friends, and family to share and gain honest information about their experiences, as well as to find resources, support, and community to help live their unique reality.

Visit http://Expose-MBC.com and share this site with your patients.

LOQTORZI® Receives a Permanent J Code: Effective July 1, 2024

Published on: July 2, 2024

Coherus is pleased to announce CMS has granted LOQTORZI® (toripalimab-tpzi) a product-specific J Code.
View Resource

Patient Selection Criteria and Surgical Resection Considerations when Evaluating Patients with Previously-Treated Advanced Melanoma

Published on: June 21, 2024

AMTAGVI (lifileucel) is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.
View Resource

On-demand: Practical Insights for Operationalizing a Lymphedema Surveillance Program

Published on: May 18, 2024

Learn about the importance of early detection and intervention for Breast Cancer-Related Lymphedema (BCRL). Hear expert insights into operationalizing a Lymphedema Surveillance Program, the role of bioimpedance spectroscopy (BIS) for early lymphedema detection, and updates on the latest clinical practice guidelines and research.
Watch Recording

The Patient Perspective: Evaluating Time and Treatment While Living with Metastatic Breast Cancer

Published on: Apr 10, 2024

Click here to view resource.

This new white paper demonstrates the time-burden on ER+, HER2- mBC patients and their loved ones when going to receive care and the potential difficulty of care when an IM injection is part of their treatment plan. It has been published by Ipsos and Living Beyond Breast Cancer, and is supported by Lilly.